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targeted call on cross border law enforcement cooperation in 
the field of drug trafficking - DG Justice/DG Migrations and 
Home Affairs (JUST/2013/ISEC/DRUGS/AG/6429) Project 
EPS/NPS (Enhancing Police Skills concerning Novel 
Psychoactive Substances; NPS). 
Abstract 
Background: 4,4′-DMAR (4,4’-dimethylaminorex; ‘Serotoni’) 
is a potent stimulant drug which has recently been associated 
with a number of fatalities in Europe. Over the last few years, 
online communities have emerged as important resources for 
disseminating levels of technical knowledge on novel 
psychoactive substances/NPS. 
Objective: Analysing the information provided by the fora 
communities on 4,4’-DMAR use, additionally critical 
reviewing the available evidence-based literature on this topic. 
Methods: Different website drug fora were identified. A critical 
review of the existing evidence-based literature was 
undertaken. Individuation and analysis of qualitative data from 
the identified website fora were performed. 
Results: The combined search results identified six website fora 
from which a range of qualitative data on recurring themes was 
collected. These themes included: routes of administration and 
doses; desired effects; adverse effects; comparison with other 
drugs; association with other drugs; medications self-
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administered to reverse 4,4’-DMAR action; overall impression; 
provision of harm reduction advice.  
Conclusions: Although being characterized by a number of 
methodological limitations, the social networks’ web 
monitoring approach (netnography) may be helpful to better 
understand some of the clinical and psychopharmacological 
issues pertaining to a range of NPS, including 4,4’-DMAR, for 
which only extremely little, if any, scientific knowledge is 
available.   
Abbreviations 
Novel psychoactive substances: NPS 
Blood brain barrier: BBB 
Dopamine transporter: DAT 
Norepinephrine transporter: NET 
Serotonin transporter: SERT 
Route of administration: ROA 
 
 
 
 
Page 3 of 37
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
 
Introduction 
Internet use has become an unremarkable aspect of everyday 
life, providing a revolutionary tool to facilitate rapid 
interpersonal communication, exchange of ideas, opinions, and 
information on a range of issues, including recreational drugs 
(Wax, 2002). 
Overall, the web represents the most popular source of 
information about NPS use (Nelson et al., 2014). In this 
respect, web fora are being extensively used as discussion areas 
(Orsolini et al., 2015). A forum moderator often oversees the 
communication activities, whilst facilitating the debate, and 
making decisions regarding the direction of threads. Apart from 
drug enthusiasts, fora members may include researchers, harm-
reduction specialists, police officers, lawyers, physicians, 
journalists and addiction specialists, all actively contributing to 
the debate (https://drugs-forum.com/index.php). 
Although fora communities are virtual, these social groups can 
have consequential effects on many aspects of the member’s 
behaviour (Kozinets, 2002) as the information being accessed 
may be misleading, or even dangerous, and particularly so for 
naïve users (Monahan & Colthurst, 2001).  
With the increase in web marketing of drugs available for 
purchase, online discussions have, however, become a reason 
for concern as they could lead to an increase in drug using 
Page 4 of 37
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5 
 
levels (Soussan & Kjellgren, 2014) whilst playing a crucial part 
in raising interest about drugs (Griffiths et al., 2010). 
4,4’-DMAR 
4,4’-DMAR (Figure 1) (IUPAC: 4-methyl-5-(4-
methylphenyl)-4,5-dihydrooxazol-2-amine), is a synthetic 
substituted oxazoline derivative which contains two chiral 
centres and two racemic mixtures (i.e. (±)-cis  and (±) trans-
racemates). Previous analytical characterizations confirmed 
that the (±)-cis racemate is the most available isomer in the 
market and the one involved in many deaths (Brandt et al., 
2014). This stimulant drug is commonly advertised as 
‘para-Methyl-4-methylaminorex’, ‘4-methyl-euphoria’, ‘4-
methyl-U4Eu’, ‘4-M-4-MAR’, ‘4,4-dimethylaminorex’ and 
‘Serotoni’.  
It belongs to the Novel Psychoactive Substance (NPS) 
category, which encompasses a wide number of compounds 
widely marketed in the ‘real’ and ‘virtual’ world as legal 
substitutes for banned drugs (Miliano et al., 2016) and 
being sometimes more harmful than their parental 
compounds in terms of toxicity, adverse reactions, 
dependence, long-term effects (Schifano et al., 2015), 
fatalities (Chiappini et al., 2015; Loi et al., 2015) and 
psychiatric consequences (Martinotti et al., 2014). 
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4,4’-DMAR was first detected in Europe in the Netherlands at 
the end of 2012, and by the first half of 2013 it had emerged in 
Denmark, Finland, Hungary, Poland, Romania, Sweden and the 
United Kingdom (EMCDDA and Europol, 2014; EMCDDA, 
2015).  
It is a research chemical most commonly sold over the Internet 
and head-shops in the form of powder and tablets, usually 
labelled ‘Speckled Cherry’ or ‘Speckled Cross’ with a variety 
of logos, colours (e.g. white, pink, green and blue) and shapes 
(EMCDDA and Europol, 2014). 
Both the tablets’ and powder composition can be considerably 
different from a product to a product as they may contain 4,4’-
DMAR alone or in combination with other psychoactive 
substances, including: synthetic cathinones, synthetic 
cannabinoids, benzofurans and ethylphenidate. To date, the 
purity of the 4,4′-DMAR available on the drug market has 
not been reported (EMCDDA, 2015).  
 As described by the EMCDDA (2015), seizures of products 
containing 4,4′-DMAR were reported in seven Member States 
(Denmark, Finland, Hungary, the Netherlands, Romania, 
Sweden and the United Kingdom), with a preferential 
availability of this substance in the Hungarian drug market.  
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In some cases, 4,4′-DMAR is offered on the illicit market as 
‘ecstasy’ and ‘amphetamine’, therefore users may not always 
be aware of the associated health risks (EMCDDA, 2015). 
Because of serious adverse effects reported, including fatal 
intoxications entirely caused by (±)-cis-4,4’-DMAR, this 
drug was banned in the UK, being placed in schedule 1 
(ACMD, 2014) of the Misuse of Drugs Act 1971. 
4,4'-DMAR is also under drug control legislation in Bulgaria; 
Croatia; Cyprus; Czech Republic; Denmark; Estonia; Finland; 
Germany; Hungary; Ireland; Lithuania; Luxembourg; 
Netherland; Norway; Poland; Slovenia; Spain; Sweden, 
Turkey, Japan (EMCDDA 2015, ELDD 2016). Additionally, 
in March 2016, the commission on Narcotic drugs decided 
to internationally control 4,4’-DMAR adding it  into 
schedule 2 of the Convention on Psychotropic Substances of 
1971. The decision became effective in November 2016 
(UNODC, 2016). 
Pharmacology  
(±)Cis-4,4′-DMAR is a monoamine-releasing agent that 
displays high potency at all three monoamine transporters. 
According to some pharmacodynamics studies, this compound 
was found to show equivalent potency at the dopamine and 
norepinephrine transporters (DAT and NET, respectively) and 
greater potency at the serotonin transporter (SERT), in 
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comparison with d-amphetamine and aminorex (Brandt et al., 
2014a). 
In another study performed on rat brain synaptosomes, the 
monoamine releasing activity of (±)cis-4,4’-DMAR and 
(±)trans-4,4’-DMAR isomers was compared to that of MDMA. 
Both cis-4,4’-DMAR and trans-4,4’-DMAR were found to be 
stronger than MDMA as releasing agents at the DAT and NET. 
Concerning the activity at SERT, (±)cis-4,4’-DMAR acted as a 
fully effective releasing agent, whereas (±)trans-4,4’-DMAR 
acted as a fully efficacious uptake blocker (McLaughlin et al., 
2014).  
Additionally, our unpublished data obtained using PreADMET 
online server (https://preadmet.bmdrc.kr/) indicate that 4,4’-
DMAR has similar predicted blood brain barrier (BBB) 
permeability as MDMA. 
To date, no published data are available on the 
pharmacokinetics of 4,4′-DMAR in animals or humans and 
no metabolites of this substance have been detected up to 
now (EMCDDA, 2015).   
Fatalities and adverse effects 
In December 2012, 4,4′-DMAR was first detected in fatalities 
reported from Sweden, followed by Denmark, Finland, 
Hungary, Romania, Sweden, France and the United Kingdom 
(EMCDDA, 2015).  
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Since October 2013, 38 4,4’-DMAR-related deaths have been 
identified in the United Kingdom (e.g. 36 in Northern Ireland 1 
in Scoltand and 1 in England); 8 in Hungary; and 1 in Poland in 
July 2013 (ACMD, 2014, Cosbey et al., 2014; EMCDDA, 
2015; Shropshire Star, 2016)  
In all 47 cases, the 4,4’-DMAR presence, either alone or in 
combination with remaining recreational drugs (e.g. cocaine, 
amphetamines, cannabis, benzodiazepines, antidepressants, 
second-generation antipsychotics, opioids and synthetic 
cathinones), was confirmed at post-mortem (ACMD, 2014, 
EMCDDA, 2015).  
Conversely, non-fatal 4,4’-DMAR acute toxicity events are 
characterized by features such as: hyperthermia, pupil dilation, 
muscular spasm, seizures, increased perspiration, cardiac and 
respiratory arrest, agitation, confusion, convulsions, 
unconsciousness and paranoid features. The presence of and/or 
interaction with other substances may account for some of the 
reported effects (EMCDDA and Europol, 2014; EMCDDA, 
2015). 
The 4,4′-DMAR activity on catecholamine transporters may be 
relevant in this respect, especially if the molecule is associated 
with recreational drugs altering dopamine and norepinephrine 
levels.  
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Indeed, psychotic episodes can occur if 4,4’-DMAR is ingested 
in combination with other catecholamine-releasing agents (e.g. 
amphetamine-type stimulants, cocaine) and cardiovascular 
issues may result from the excessive systemic levels of 
norepinephrine released. 
Additionally, the risk of experiencing a serotonergic syndrome 
may be increased by the association of 4,4’-DMAR with 
compounds affecting either the serotonin release (e.g. 
MDMA/ecstasy) or its reuptake, such as the selective serotonin 
reuptake inhibitors (SSRIs) (McLaughlin et al., 2014). 
We aimed here at reviewing the literature relating to 4,4’-
DMAR intake. Furthermore, we aimed at describing, through 
an assessment of related anecdotal online reports, a range of 
clinical pharmacological issues to its misusing issues potential. 
Methods 
To identify peer-reviewed papers and online reports 
commenting on 4,4’-DMAR misuse issues, a comprehensive 
search on the Embase, Scopus; Google Scholar and 
Pubmed/Medline databases was performed using the following 
key words: (4,4’-DMAR) AND (abuse OR misuse OR 
poisoning OR dependence OR addiction). No language or time 
restrictions were placed on the electronic search; focus was on 
both pre-clinical and clinical data and covered the period up to 
November 15th, 2016.  
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To identify information on 4,4’-DMAR misusers’ first-hand 
experiences, a qualitative/observational, i.e. netnographic, 
approach on selected websites was carried out. In doing so, 
between March and October 2016, a range of qualitative 
Google searches was carried out, in English, using key words 
such as ‘4,4’-DMAR and abuse’, ‘4,4’-DMAR and misuse’; 
‘4,4’-DMAR and experience’; ‘Serotoni and forum’; ‘Speckled 
Cherry forum’; ‘Speckled Cross forum’; ‘Para-Methyl-4-
Methylaminorex forum’; ‘4-methyl-euphoria forum’; ‘4-
methyl-U4Eu forum’; ‘4,4-dimethylaminorex forum’.  
The first 2 pages/20 hits per keyword (e.g. 60 per language;  
120 links) were considered. A number of websites were 
subsequently excluded, because: not relevant; being duplicates; 
or requiring a registration/payment procedure. 
A total of six sites hosting forum activity around 4,4’-DMAR 
use were identified:  
1. https://www.chemsrus.com;  
2. https://www.reddit.com;  
3. https://www.ukchemicalresearch.org;  
4. http://www.bluelight.org; 
5. http://www.psychonaut.com/forum.php;  
6. https://drugs-forum.com.  
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Overall, twenty detailed posts (19 in English, and 1 in French) 
focusing on 4,4’-DMAR use were found and individually 
analysed by identifying the common topics and patterns of 
discussion. Conversely, a range of fora posts/threads relating to 
a few 4,4’-DMAR themes, including:  
1. routes of administration and doses  
2. desired effects  
3. adverse effects  
4. comparisons with other substances  
5. concurrent intake with other drugs 
6. medication use to counteract 4,4’-DMAR action  
7. overall impression 
8. availability of harm reduction messages; warning other 
people regarding possible drug-related health risks 
were specifically analysed. No posts/other contributions to fora 
discussions were made, and no information or clarification of 
content was sought by the researchers. 
 Ethical consideration 
Our research involved the collection and characterization of 
already existing reports published on public Internet fora. A 
discrete approach was undertaken, and no interactions with fora 
members were made.  In order to preserve the anonymity of the 
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fora members, users’ nicknames were not mentioned and the 
quotes were not integrally reported.  Ethics’ approval for the 
study was granted by the University of Hertfordshire School of 
Pharmacy Ethics Committee, on December 15th, 2010 
(reference code PHAEC/10-42), with a further 5-year extension 
of the approval having been granted in November 2013.  
Results 
Literature identification and analysis 
 
The comprehensive literature search led to the identification of 
13 peer-reviewed papers and 3 reports (EMCDDA and 
Europol, 2014; ACMD, 2014; EMCDDA, 2015) focusing on 
4,4’-DMAR use, which were critically analysed. 
Published information on routes of administration (ROA), 
suggest that nasal insufflation and oral consumption practices 
are the most widely used followed by inhalation and injection 
(ACMD, 2014; EMCDDA and Europol, 2014; EMCDDA, 
2015; Cosbey et al., 2014; Coppola et al., 2015; Glanville et al., 
2015; Hentig, 2016).  
Oral doses were described ranging from 10 to 200 mg, while 
the insufflated ones vary from 10 to 65 mg (ACMD, 2014; 
EMCDDA and Europol, 2014; EMCDDA, 2015; Coppola et 
al., 2015; Glanville et al., 2015; Nizar et al., 2015; Hentig, 
2016).  
Oral consumption was reported to be commonly practiced by 
directly ingesting tablets/powder or by swallowing powder 
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previously wrapped in cigarette papers (‘bombing’) (ACMD, 
2014; EMCDDA and Europol, 2014; EMCDDA, 2015; Cosbey 
et al., 2014; Coppola et al., 2015; Glanville et al., 2015).  
Commonly reported desired effects include: euphoria, 
increased sociability and energy, alertness, and increased 
confidence; while untoward effects vary from increased heart 
rate, hyperthermia, sweating, agitation, jaw clenching 
(bruxism), facial spasms, stimulation, nausea, dysphoria, 
dilated pupils, to psychosis and hallucinations (ACMD, 2014; 
EMCDDA and Europol, 2014; EMCDDA, 2015; Cosbey et al., 
2014; Coppola et al., 2015; Glanville et al., 2015).  
The use of a range of sedatives and anxiolytics was reported as 
a common practice to reverse 4,4’-DMAR long-lasting 
stimulants’ effects (12-16 hours) (Glanville et al., 2015; 
Schifano et al., 2016).  
Desired and untoward effects were described to be comparable 
to those observed with other stimulant-type drugs (e.g. MDMA, 
mephedrone) characterized by similar pharmacology and 
pharmacokinetic properties (Brandt et al., 2014a; McLaughlin 
et al., 2014; Schifano et al., 2015, 2016; Nils et al., 2016; 
Hentig, 2016; Lucchetti et al., 2016). 
Combination with other drugs (e.g. synthetic cathinones, 
amphetamines, cocaine) has been widely reported and 
accounted for several toxicity events (e.g. cardiovascular 
effects, psychotic symptoms, agitation hyperthermia) and 
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fatalities (Brandt et al., 2014b; ACMD, 2014; EMCDDA and 
Europol, 2014; EMCDDA, 2015; Cosbey et al., 2014; Coppola 
et al., 2015; Glanville et al., 2015; Berg, 2016; Hentig, 2016). 
Social cohesion, support, and harm reduction advice have been 
also widely described among a range of NPS users (Soussan & 
Kjellgren, 2014). 
Self-reported routes of administration and dosages  
Dosages and routes of administration were found to be a 
widely-debated topic of discussion. Overall users tended to 
specify doses, frequency of re-dosing and the combination of 
different ROA to achieve the optimal ‘high level’. The 
indication of dosages and ROAs was reported by 85% (17/20) 
of users. Among them, 76% (13/17) described oral use, 12% 
(2/17) reported the intranasal ROA or vaping, 12% (2/17) 
reported a multiple re-dosing practice describing an oral 
ingestion followed by the intranasal route, or by snorting and 
vaping. The formulations described were powder and pellets. 
The oral doses ranged from 10 to 120 mg; the intranasal ones 
varied from 25 to 30 mg and the vaporised doses were in the 
10-60 mg range (Figure 2). A quarter of users (5/20) described 
a slow onset of the drug’s psychoactive effects (Figure 2). 
Self-reported desired and untoward effects 
Intensity and duration of the ‘positive’ effects were widely 
reported; 70% (14/20) of users described a range of positive 
effects including: stimulation, energy increase, euphoria, 
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relaxation, increased sociability, empathy, disinhibition, arousal 
(Figure 2). 
By contrast, a range of adverse effects was described by 55% of 
users (11/20) and included: hallucinations, altered perceptions, 
insomnia, queasiness, jaw clenching/tension/bruxism, blurry 
vision, nystagmus, psychosis, confusion, nausea, sweatiness, 
increased heart rate, and hyperthermia (Figure 3). 
The effects of 4,4’-DMAR were compared with those 
associated with other stimulant (e.g. 4FA, MDMA, 6-APB, 
APB, 3-MMC, 4-MMC, MDPV a-PVP, 4-MMA, MDMA) 
intake by 50% of the users (10/20). Comments included: “Way 
better than cathinones!…it was also way way better than 4-FA 
which never really felt serotonergic to me”;…“It definitely felt 
stronger than any of my experiences on 6-APB though”;…“I 
found it to be a very nice experience, somewhat comparable to 
3-MMC but a lot longer lasting and thus with a lot less 
craving”) (Figure 3). 
Association with other recreational drugs 
Some 30% (6/20) of users used 4,4’-DMAR with other drugs, 
especially alcohol (66%; 4/6); 6-APB (17%; 1/6); and 
phenylpiracetam (17%, 1/6) (Figure 3).  
Some users described a potentiation of 4,4’-DMAR effects 
whilst on alcohol (“definitely potentiated with alcohol”); and a 
feeling of “head clearness” (“Normally I would become sloppy 
and hazy with alcohol, but this was clear and fresh”). Finally, 
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to cope with social anxiety issues, 4,4’-DMAR was associated 
with either alcohol or 6-APB. 
Medication(s) self-administered to revert 4,4’-DMAR action 
Since 4,4’-DMAR stimulant effects seemed to be quite long-
lasting, some 20% of users (4/20) stated they had used 
sedatives/anxiolytics (e.g. diazepam, zolpidem, trazodone, 
baclofen, flubromazepam, and etizolam) (Figure 3). 
Overall impression 
Some 50% (10/20) of fora users provided their peers with either 
a positive or a negative summary of their 4,4’-DMAR personal 
experiences, hence to promote or denigrate the use of this drug 
(Figure 4). Indeed, most of them described their experience as 
“awesome”, “enjoyable”, “nice”, “clean”, “comfortable” 
while others considered it “disappointing”. Other users 
described their experience using technical language which 
involved a reference to the molecule’s pharmacodynamics (“I 
really liked the dopamine-serotonin activation ration”); 
pharmacokinetics (“…a biphasic effect with a stimulation 
predominant on the side end…residual stimulation the day 
after”); or addictive liability levels (“significative addictive 
potential”). 
Overall, some users appeared enthusiastic (“I think it’s the most 
beautiful, awesome stimulant I’ve ever tried”…“to me this feels 
like a product the market has been seriously lacking for a long 
time”). 
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Harm reduction advice 
Some fora discussions identified here were characterized by a 
general concern for safety, with some 30% (6/20) of users 
providing a range of advice, including: avoiding concurrent 
ingestion of other drugs both on the intake day and for a few 
days after 4,4’-DMAR use; being careful about both the dosage 
self-administered and tendency to re-dosing, whilst considering 
the 4,4’-DMAR intensity of the psychoactive effects (“this is 
not a functional/nootropic stimulant, this is a more potent 
version of MDMA/APB”) (Figure 4). 
Discussion 
4,4’-DMAR popularity in a range of different countries may 
well be related to both its significant psychoactive effects and 
the current intense web-based marketing activities (EMCDDA 
and EUROPOL, 2014).  
This drug belongs to the category of NPS which includes 
numerous harmful substances like: “Synthetic 
Cannabinoids” (the largest group of new drugs monitored 
by the EMCDDA  and found to be highly toxic according to 
the high affinity and efficacy at the level of the neural CB1 
receptors) (EMCDDA, 2016; Santacroce et al., 2015; De 
Luca et al., 2015); “Synthetic Cathinones” (the second 
widest group monitored by the EMCDDA, implicated in a 
number of overdose deaths  and serious 
sympathomimetic adverse effects) (EMCDDA, 2016);  
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“hallucinogens” (including compounds like 25I- and 25C-
NBoMe, responsible for acute and chronic toxicities, 
according to their ability to act at the level of the 
serotoninergic system)  (Bersani et al., 2014 ).  
The public health risks related to 4,4′-DMAR use may be 
associated with a range of factors, including: drug availability; 
quality and purity; levels of risk awareness amongst users; and 
potential combination of this drug with other substances (e.g. 
entactogens, stimulants and/or depressants including alcohol) 
(EMCDDA, 2015; EMCDDA and Europol, 2014). 
Much of our knowledge about 4,4’-DMAR comes from 
retrospective self-reports from recreational users (e.g. the ‘e-
psychonauts’, Orsolini et al., 2015) who use the fora as a 
widely available platforms to disseminate a range of drug-
related personal experiences. 
According to previous reports (ACMD, 2014; EMCDDA and 
Europol, 2014), the main 4,4’-DMAR routes of administration 
include oral ingestion, at a dosage of 10-200 mg per occasion, 
and nasal insufflation (10-65 mg dosage), with injection having 
been only rarely reported.  
In the present study, fora users have been widely sharing their 
4,4’-DMAR intake experiences and knowledge, with most 
(80%) messages having been posted in 2013, e.g. in parallel 
with first seizures of the drug in the EU. Starting from 2015, 
the online discussions focusing on this drug, rapidly 
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disappeared from the surface web,  in parallel with 4,4'-
DMAR being banned in different countries.  
This tendency was already observed with other substances, 
such as 2C-T-7, a stimulant drug which rapidly 
disappeared from the cyber market after control legislation 
(Schifano et al., 2005). However, this does not excluded the 
possibility of a move of 4,4’-DMAR-related  illegal activities 
into the ‘deep web’, as already observed with other 
controlled substances (Orsolini et al., 2015).  Moreover, the 
fall noted in deaths involving this molecule in 2015 
(Corkery, 2016) may be due, in part, to the control of this 
substance. Equally, the fall may be due to fewer individuals 
using it following the bad reputation it received because of 
the sudden outbreaks of these severe adverse effects. 
Overall, fora users mostly ingested 4,4’-DMAR powder and 
pellets, at dosages (e.g. 10-120 mg) consistent with previous 
reports (ACMD, 2014; EMCDDA and Europol, 2014), 
although vaping and snorting ROAs were at times preferred, 
with multiple re-dosing practice being described as quite a 
popular approach.  
Most of the 4,4’-DMAR fora enthusiasts described here seemed 
to present with a previous history of drug misuse, whilst 
possessing large levels of technical/pharmacological 
knowledge regarding NPS and 4,4’-DMAR in particular, hence 
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well resembling the classical/standard ‘e-psychonauts’ 
description.   
The present report seems to confirm that 4,4’-DMAR is a 
popular recreational drug which, similarly to remaining 
stimulants, is associated with feelings of stimulation, euphoria, 
energy, alertness, increasing confidence. The powerful ‘pro-
social’ effects (e.g. increased empathy, feelings of friendliness, 
interpersonal closeness, openness) were here particularly 
emphasized (EMCDDA and Europol, 2014). Related stimulant 
effects seemed to be characterized by a significant lag time, 
peaking in 2-5 hours, but were long-lasting (e.g. 12-16 hours) 
as well (Glanville et al., 2015). 
Consistent with previous studies (Glanville et al., 2015), 
untoward effects were here described in some 55% of users, 
starting from the minimal (e.g. 5mg) dosage, and included: 
nausea, dysphoria, agitation, confusion, aggression, sweating, 
increased heart rate, hyperthermia, dilated pupils, psychosis, 
hallucinations, insomnia, jaw clench/jaw tension/bruxism, 
blurry vision, nystagmus. 
Both the psychoactive (including the entactogenic and 
nootropic properties) and the adverse effects being here 
described are consistent with 4,4’-DMAR being a 
phenethylamine/MDMA like compound (Bershad et al., 2016; 
Schifano et al., 2016; Iversen, 2013; Miliano et al., 2016).  
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The 4,4’-DMAR pharmacodynamics profile may be broadly 
similar to that of other stimulants. However, because of both 
the intensity and the long-duration of its effects, the 4,4’-
DMAR intake may be a reason of particular concern, and 
especially so if the molecule, as here described by 30% of 
users, is ingested in combination with remaining 
serotonergic/dopaminergic compounds (Coppola et al., 2014). 
These peculiar clinical pharmacological characteristics may 
help explaining the disturbingly high rate of 4,4’-DMAR 
fatalities observed over a relatively short period of time in the 
EU and especially in Northern Ireland (EMCDDA and Europol, 
2014).  
To counteract the long-lasting stimulant effects, it is of interest 
to note that some 20% of users here allegedly self-administered 
with a range of sedatives, including designer/’exotic’ 
benzodiazepines (Schifano et al., 2016). In this way, users were 
arguably adding further health risks to the already risky 
practice of ingesting a powerful, but virtually unknown to the 
medical literature, stimulant such as 4,4’-DMAR. 
Limitations  
There are a number of possible limitations of the present study; 
a multi-lingual analysis of a larger sample of websites could 
have provided better levels of information. Furthermore, only 
publicly available web sites/fora were monitored here, and 
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further data of interest could possibly have been identified by 
the analysis of the ‘deep web’ and ’dark net’ material (Orsolini 
et al., 2015). We made no 4,4’-DMAR purchase attempts, 
hence one could argue about the product content/dosage being 
delivered. Overall, anecdotal reports are only partially reliable 
and it may be inappropriate to trust information obtained from 
the internet without independent verification. Additionally, 
there is no certainty that multiple threads or posts were 
generated by different individuals, as it is not unusual that 
people can access the fora multiple times with different 
pseudonyms. 
Since very few peer-reviewed papers relating to 4,4’-DMAR 
misuse issues were identified, the present conclusions mainly 
relied on sources (e.g. web sites) are characterized by levels of 
unreliability. Only large-scale, adequately controlled, clinical 
studies can give a clear indication of a drug characteristics and 
adverse effects. However, in line with present observations, 
previous studies (Corkery et al., in press) Schifano et al., 2010; 
Soussan & Kjellgren, 2014; 
https://www.drugabuse.gov/publications/drugfacts/nationwide-
trends) have clearly suggested that the increase in online 
trafficking/debate about a specific psychoactive drug typically 
precedes the occurrence of clinical incidents at the population 
level.  
Conclusions 
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This study suggests that fora members co-operate in 
exchanging an extensive body of knowledge about NPS, 
including 4,4’-DMAR.  The combination of sensation seeking, 
harm-reduction, and social networks’ pressure may arguably 
have detrimental effects on many aspects of fora members’ 
drug intake behaviour. The issue of 4,4’-DMAR misuse may be 
a reason for concern; consumers may not be fully aware of the 
pharmacological activity, and possible medical consequences, 
of the compound(s) they are ingesting. Indeed, 4,4’-DMAR 
misuse may often occur in the context of polydrug intake, and 
the pharmacodynamics/pharmacokinetics’ interactions of 4,4’-
DMAR with other substances are not known.  
Further analyses should be undertaken to better draft a risk 
profile for this drug. As with any centrally active drug, 
physicians should carefully evaluate patients for history of drug 
abuse and observe them for signs of any products’, including 
4,4’-DMAR, misuse. Additionally, prevention strategies should 
be developed and better public awareness levels should be 
promoted. 
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Figure 1: 4,4’-DMAR chemical structure 
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Figure 2: 4,4’DMAR self-reported routes of administration and 
dosages; long onset awareness; self-reported desired effects 
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Figure 3: 4,4’-DMAR self-reported untoward effects; self-reported 
comparisons with other substances; self-reported association with 
other drugs; self-reported medications use to revert 4,4’-DMAR 
action. 
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Figure 4: Self-reported overall impression; harm reduction advice 
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